{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:16:28Z","timestamp":1790223388275,"version":"4.1.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.semarthrit.2015.10.010","type":"journal-article","created":{"date-parts":[[2015,11,3]],"date-time":"2015-11-03T08:08:50Z","timestamp":1446538130000},"page":"604-610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":109,"title":["Dyslipidemia in systemic lupus erythematosus: just another comorbidity?"],"prefix":"10.1016","volume":"45","author":[{"given":"Konstantinos","family":"Tselios","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalambos","family":"Koumaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray B.","family":"Urowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2015.10.010_bib1","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.21955","article-title":"Mortality in systemic lupus erythematosus","volume":"54","author":"Bernatsky","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib2","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.30277","article-title":"Life expectancy, standardized mortality ratios and causes of death in six rheumatic diseases in Hong Kong, China","volume":"63","author":"Mok","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib3","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1160\/TH11-05-0330","article-title":"The problem of accelerated atherosclerosis in systemic lupus erythematosus: insights into a complex co-morbidity","volume":"106","author":"Wade","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrrheum.2012.14","article-title":"Accelerated atherosclerosis in patients with SLE\u2014mechanisms and management","volume":"8","author":"Skaggs","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib5","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/ki.2010.525","article-title":"Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus","volume":"79","author":"Reich","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib6","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/art.21929","article-title":"Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus","volume":"54","author":"Tisseverasinghe","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib7","article-title":"Clinical outcomes and risk factors for posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a multicentric case\u2013control study","author":"Merayo-Chalico","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib8","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.autrev.2015.01.010","article-title":"Twenty-year brain magnetic resonance imaging follow-up study in systemic lupus erythematosus: factors associated with accrual of damage and central nervous system involvement","volume":"14","author":"Piga","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1177\/0961203307081113","article-title":"Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort","volume":"16","author":"Urowitz","year":"2007","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib10","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/art.23353","article-title":"Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort","volume":"59","author":"Urowitz","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib11","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1002\/art.20622","article-title":"Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events","volume":"50","author":"Toloza","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00296-007-0447-x","article-title":"Prevalence and factors associated with dyslipoproteinemias in Brazilian systemic lupus erythematosus patients","volume":"28","author":"Cardoso","year":"2008","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib13","first-page":"132","article-title":"The proportion of dyslipidemia in systemic lupus erythematosus patient and distribution of correlated factors","volume":"37","author":"Wijaya","year":"2005","journal-title":"Acta Med Indones"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib14","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1191\/0961203304lu1084xx","article-title":"The prevalence of dyslipoproteinemia in Thai patients with systemic lupus erythematosus","volume":"13","author":"Siripaitoon","year":"2004","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib15","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1177\/0961203309359781","article-title":"Metabolic syndrome in patients with systemic lupus erythematosus: association with traditional risk factors for coronary heart disease and lupus characteristics","volume":"19","author":"Telles","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib16","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1440-1797.2011.01456.x","article-title":"Dyslipidaemia in patients with lupus nephritis","volume":"16","author":"Chong","year":"2011","journal-title":"Nephrology"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib17","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clinbiochem.2004.10.006","article-title":"Evidence of reduced plasma HDL subfractions in patients with cutaneous discoid lupus erythematosus","volume":"38","author":"Lagogianni","year":"2005","journal-title":"Clin Biochem"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib18","first-page":"2112","article-title":"Predictors of lipid abnormalities in children with new-onset systemic lupus erythematosus","volume":"34","author":"Tyrrell","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/1746-1596-8-175","article-title":"The positive correlations of apolipoprotein E with disease activity and related cytokines in systemic lupus erythematosus","volume":"8","author":"Song","year":"2013","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib20","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/art.1780361111","article-title":"Low levels of total cholesterol, high-density lipoprotein and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus","volume":"36","author":"Lahita","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib21","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1191\/096120398678920262","article-title":"Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE","volume":"7","author":"Dinu","year":"1998","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib22","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1182\/blood.V97.8.2381","article-title":"Apolipoprotein A-I inhibits the production of interleukin-1 and tumor necrosis factor by blocking contact-mediated activation of monocytes by T lymphocytes","volume":"97","author":"Hyka","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/cei.12651","article-title":"Decreased levels of autoantibodies against apolipoprotein B-100 antigens are associated with cardiovascular disease in systemic lupus erythematosus","volume":"181","author":"Svenungsson","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib24","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/acr.22430","article-title":"Apolipoprotein-containing lipoprotein subclasses and subclinical atherosclerosis in systemic lupus erythematosus","volume":"67","author":"Kiani","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib25","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/096120339700600610","article-title":"Dyslipoproteinemias in systemic lupus erythematosus: influence of disease activity and anticardiolipin antibodies","volume":"6","author":"Borba","year":"1997","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/VHRM.S17015","article-title":"Prevalence of LDL atherogenic phenotype in patients with systemic lupus erythematosus","volume":"7","author":"Olusi","year":"2011","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib27","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/03009740802541470","article-title":"Dyslipidaemia and lipoprotein pattern in systemic lupus erythematosus (SLE) and SLE-related cardiovascular disease","volume":"38","author":"Hua","year":"2009","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib28","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0022-2275(20)37569-6","article-title":"Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis","volume":"37","author":"Goldberg","year":"1996","journal-title":"J Lipid Res"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib29","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/1529-0131(200005)43:5<1033::AID-ANR11>3.0.CO;2-B","article-title":"Chylomicron metabolism is markedly altered in systemic lupus erythematosus","volume":"43","author":"Borba","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib30","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.autrev.2007.11.016","article-title":"Systemic lupus erythematosus and lupus dyslipoproteinemia","volume":"7","author":"De Carvalho","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib31","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1002\/art.20630","article-title":"Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus?","volume":"50","author":"De Carvalho","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib32","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1002\/art.10624","article-title":"Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus","volume":"46","author":"Reichlin","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1875-9572(08)60009-1","article-title":"Systemic lupus erythematosus associated with extreme hypertriglyceridemia","volume":"49","author":"Huang","year":"2008","journal-title":"Pediatr Neonatol"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib34","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1053\/meta.2002.34695","article-title":"Lipid compositional differences of small, dense low-density lipoprotein particle influence its oxidative susceptibility: possible implication of increased risk of coronary artery disease in subjects with phenotype B","volume":"51","author":"Ohmura","year":"2002","journal-title":"Metabolism"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib35","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/art.20780","article-title":"Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations","volume":"52","author":"Frostegard","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib36","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1172\/JCI118345","article-title":"Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell co-cultures","volume":"96","author":"Van Lenten","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib37","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1194\/jlr.R400001-JLR200","article-title":"The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL","volume":"45","author":"Navab","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib38","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1002\/art.24677","article-title":"Dysfunctional proinflammatory high-density lipoprotein confers increased risk for atherosclerosis in women with systemic lupus erythematosus","volume":"60","author":"McMahon","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.autrev.2009.03.001","article-title":"The therapeutic potential of targeting B cells and anti-oxLDL antibodies in atherosclerosis","volume":"9","author":"Van Leeuwen","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib40","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/0140-6736(93)91213-6","article-title":"Cross-reaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus","volume":"341","author":"Vaarala","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib41","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/rheumatology\/keg248","article-title":"Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome","volume":"42","author":"Delgado Alves","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib42","article-title":"Single test isolated lupus anticoagulant positivity is associated with increased plasma levels of inflammatory markers and dyslipidemia","author":"Just","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib43","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1196\/annals.1361.073","article-title":"OxLDL\/beta2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis and antiphospholipid syndrome: pathogenic implications for vascular involvement","volume":"1051","author":"Lopez","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib44","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1191\/0961203306lu2267oa","article-title":"Oxidized low-density lipoprotein and beta2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis","volume":"15","author":"Lopez","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib45","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1200\/JCO.1988.6.8.1328","article-title":"A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients","volume":"6","author":"Feinberg","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib46","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1084\/jem.161.5.984","article-title":"Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells","volume":"161","author":"Beutler","year":"1985","journal-title":"J Exp Med"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib47","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1002\/art.11264","article-title":"Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha\/tumor necrosis factor receptor system in systemic lupus erythematosus","volume":"48","author":"Svenungsson","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib48","first-page":"539","article-title":"Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors","volume":"33","author":"Asanuma","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib49","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJM199902113400607","article-title":"Acute-phase proteins and other systemic responses to inflammation","volume":"340","author":"Gabay","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib50","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/MOL.0b013e32832ac03e","article-title":"Human C-reactive protein and the metabolic syndrome","volume":"20","author":"Devaraj","year":"2009","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib51","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.2169\/internalmedicine.50.4297","article-title":"Examination of adhesion molecules, homocysteine and hs-CRP in patients with polygenic hypercholesterolemia and isolated hypertriglyceridemia","volume":"50","author":"Calan","year":"2011","journal-title":"Intern Med"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib52","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1002\/art.34541","article-title":"High-sensitivity C-reactive protein as a marker of cardiovascular risk in systemic lupus erythematosus","volume":"64","author":"Nikpour","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib53","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1191\/096120301669070811","article-title":"Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients","volume":"10","author":"Formiga","year":"2001","journal-title":"Lupus"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2015.10.010_bib54","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000314213","article-title":"Pathophysiology of dyslipidemia in Cushing\u05f3s syndrome","volume":"92","author":"Arnaldi","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib55","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1177\/0961203312450084","article-title":"Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect","volume":"21","author":"Cairoli","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib56","first-page":"325","article-title":"The cholesterol lowering effect of anti-malarial drugs is enhanced in patients with lupus taking corticosteroid drugs","volume":"26","author":"Rahman","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib57","first-page":"2142","article-title":"Effect of anti-malarial agents on the fasting lipid profile in systemic lupus erythematosus","volume":"27","author":"Tam","year":"2000","journal-title":"J Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2015.10.010_bib58","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1177\/096120339600500105","article-title":"Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis","volume":"5","author":"Petri","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib59","first-page":"397","article-title":"Cyclosporine A in the long term management of systemic lupus erythematosus","volume":"25","author":"Germano","year":"2011","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib60","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1440-1797.2012.01646.x","article-title":"Proliferation signal inhibitors in the treatment of lupus nephritis: preliminary experience","volume":"17","author":"Yap","year":"2012","journal-title":"Nephrology"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib61","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1177\/0961203311411347","article-title":"Implications of immunosuppressive agents in cardiovascular risk and carotid intima media thickness among lupus nephritis patients","volume":"20","author":"Sazliyana","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib62","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/oxfordjournals.aje.a009122","article-title":"Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study","volume":"145","author":"Manzi","year":"1997","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib63","article-title":"Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis","author":"Ballocca","year":"2014","journal-title":"Eur J Prevent Cardiol"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib64","doi-asserted-by":"crossref","first-page":"R156","DOI":"10.1186\/ar3473","article-title":"Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study","volume":"13","author":"Nikpour","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib65","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1191\/096120300669204787","article-title":"Vascular events in hypertensive patients with systemic lupus erythematosus","volume":"9","author":"Rahman","year":"2000","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib66","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/rheumatology\/ker339","article-title":"Ability of non-fasting and fasting triglycerides to predict coronary artery disease in lupus patients","volume":"51","author":"Touma","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib67","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/03009740600557256","article-title":"Atherosclerosis in Asian Indians with systemic lupus erythematosus","volume":"35","author":"Bhatt","year":"2006","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib68","first-page":"18","article-title":"Cardiovascular risk and lupus disease","volume":"30","author":"Boucelma","year":"2011","journal-title":"Int Angiol"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib69","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/art.11418","article-title":"Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus","volume":"50","author":"Selzer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib70","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1093\/rheumatology\/ker285","article-title":"Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus","volume":"50","author":"Kiani","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib71","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/acr.21782","article-title":"Association of systemic lupus erythematosus with angiographically-defined coronary artery disease: a retrospective cohort study","volume":"65","author":"Kaul","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib72","first-page":"2137","article-title":"Natural history of hypercholesterolemia in systemic lupus erythematosus","volume":"26","author":"Bruce","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib73","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/art.23196","article-title":"Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus","volume":"58","author":"Thompson","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib74","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1177\/0961203314537696","article-title":"The correlation between carotid artery atherosclerosis and clinical ischemic heart disease in lupus patients","volume":"23","author":"Eder","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib75","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s10067-011-1910-3","article-title":"Frequency of established cardiovascular disease and its risk factors in Chinese patients with systemic lupus erythematosus","volume":"31","author":"Wang","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib76","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1177\/0961203308099625","article-title":"Arterial wall dysfunction in systemic lupus erythematosus","volume":"18","author":"Cypiene","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib77","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.3899\/jrheum.090011","article-title":"Risk factors for development of coronary artery disease in women with systemic lupus erythematosus","volume":"36","author":"Goldberg","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib78","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.atherosclerosis.2012.08.029","article-title":"Complement system and small HDL particles are associated with subclinical atherosclerosis in SLE patients","volume":"225","author":"Parra","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib79","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa035611","article-title":"Premature coronary-artery atherosclerosis in systemic lupus erythematosus","volume":"349","author":"Asanuma","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib80","first-page":"716","article-title":"Role of lipids in the progression of renal disease in systemic lupus erythematosus patients","volume":"112","author":"Luzar","year":"2000","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib81","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1177\/0961203313505927","article-title":"Renoprotective strategies in lupus nephritis: beyond immunosuppression","volume":"22","author":"Griffin","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib82","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1212\/01.WNL.0000149640.78684.EA","article-title":"Predictors of cognitive dysfunction in patients with systemic lupus erythematosus","volume":"64","author":"MaLaurin","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib83","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3899\/jrheum.090829","article-title":"Pancreatitis in systemic lupus erythematosus: frequency and associated factors\u2014a review of the Hopkins Lupus Cohort","volume":"37","author":"Makol","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib84","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/rheumatology\/kem186","article-title":"Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial","volume":"46","author":"Ferreira","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib85","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/art.30645","article-title":"Use of atorvastatin in systemic lupus erythematosus in children and adolescents","volume":"64","author":"Schanberg","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib86","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/annrheumdis-2012-202315","article-title":"Secondary analysis of the APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal patients with higher C reactive protein","volume":"73","author":"Ardoin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib87","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/acr.20440","article-title":"Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial","volume":"63","author":"Mok","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib88","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1136\/ard.2009.109405","article-title":"Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus","volume":"68","author":"De Kruif","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib89","doi-asserted-by":"crossref","first-page":"R117","DOI":"10.1186\/ar3402","article-title":"Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study","volume":"13","author":"Plazak","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib90","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/ard.2010.136762","article-title":"Lupus Atherosclerosis Prevention Study (LAPS)","volume":"70","author":"Petri","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib91","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00296-007-0341-6","article-title":"A pravastatin dose-escalation study in systemic lupus erythematosus","volume":"27","author":"Costenbader","year":"2007","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib92","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.24379","article-title":"Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study","volume":"60","author":"Norby","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib93","first-page":"162","article-title":"Effects of statins on proinflammatory\/prothrombotic biomarkers and on disease activity scores in SLE patients: data from LUMINA (LXXVI), a multi-ethnic US cohort","volume":"32","author":"Willis","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib94","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ijcard.2012.09.190","article-title":"Efficacy and safety of statins in the prevention of atherosclerosis in patients with systemic lupus erythematosus. A meta-analysis of randomized controlled trials","volume":"167","author":"Ye","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib95","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/art.21441","article-title":"Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus","volume":"53","author":"Costenbader","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib96","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cjca.2012.11.032","article-title":"2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"29","author":"Anderson","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib97","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","article-title":"European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib98","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1177\/0961203306071870","article-title":"Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus","volume":"15","author":"Chung","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib99","first-page":"1","article-title":"Adjusted Framingham risk factor scoring for systemic lupus erythematosus","author":"Urowitz","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib100","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/0961203306069972","article-title":"Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus","volume":"15","author":"De Leeuw","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib101","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jbspin.2012.08.014","article-title":"Do all lupus patients need statins?","volume":"80","author":"Soubrier","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib102","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/0961203307079566","article-title":"Management of dyslipidemia in children and adolescents with systemic lupus erythematosus","volume":"16","author":"Ardoin","year":"2007","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib103","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1136\/ard.2010.133827","article-title":"Statin therapy in lupus-mediated atherogenesis: two birds with one-stone?","volume":"70","author":"Van Leuven","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib104","doi-asserted-by":"crossref","first-page":"R93","DOI":"10.1186\/ar3020","article-title":"Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine model of accelerated atherosclerosis","volume":"12","author":"Woo","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib105","doi-asserted-by":"crossref","first-page":"7641","DOI":"10.4049\/jimmunol.173.12.7641","article-title":"Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black\/white F1 mice","volume":"173","author":"Lawman","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib106","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1002\/art.23605","article-title":"Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus","volume":"58","author":"Graham","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib107","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.4049\/jimmunol.177.5.3028","article-title":"Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model","volume":"177","author":"Aprahamian","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib108","doi-asserted-by":"crossref","first-page":"7416","DOI":"10.4049\/jimmunol.177.10.7416","article-title":"Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus","volume":"177","author":"Jury","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib109","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1002\/art.27478","article-title":"Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, function as inhibitors of cellular and molecular components involved in type I interferon production","volume":"62","author":"Amuro","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib110","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/0961203310364400","article-title":"Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus","volume":"19","author":"Ferreira","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib111","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.atherosclerosis.2012.02.023","article-title":"Dual effects of statins therapy in systemic lupus erythematosus and SLE-related atherosclerosis: the potential role of regulatory T cells","volume":"222","author":"Tu","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib112","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/rheumatology\/keh035","article-title":"Statins and lupus erythematosus","volume":"43","author":"Noel","year":"2004","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib113","doi-asserted-by":"crossref","DOI":"10.1097\/MJT.0b013e31828e5bfb","article-title":"Statins as a potential risk factor for autoimmune diseases: a case report and review","author":"John","year":"2013","journal-title":"Am J Ther"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib114","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1177\/0961203312436861","article-title":"Statin-induced lupus: a case\/non-case study in a nationwide pharmacovigilance database","volume":"21","author":"Moulis","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib115","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.semarthrit.2011.06.002","article-title":"Association between statin use and lupus-like syndrome using spontaneous reports","volume":"41","author":"De Jong","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.10.010_bib116","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1468-3083.2006.01838.x","article-title":"Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review","volume":"21","author":"Noel","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215002711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215002711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T05:39:46Z","timestamp":1718170786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017215002711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":116,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0049017215002711"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.10.010","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dyslipidemia in systemic lupus erythematosus: just another comorbidity?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}